Pay in 4 interest-free payments of $6.58 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
& Paulmurugan, R
intravenous TB-4 Phase 1 safety and pharmacokinetics, no dose-limiting or serious adverse events (Ann N Y Acad Sci 2010;1194:223229): NCT00743769 Centers for Disease Control and Prevention
Additional benefits include metabolic enhancement without growth hormone side effects, no impact on blood glucose or insulin sensitivity, potential increases in energy expenditure through thermogenic mechanisms, and compatibility with athletic training and performance goals
METAOD006 lasted 24 weeks This larger randomized trial enrolled 534 adults, with 502 receiving a study treatment
Expression of the HMGCS2 gene is positively regulated via glucagon signal transduction events and negatively regulated by insulin signal transduction events (see Regulation of Ketogenesis below)
US$ 24.33
US$ 27.55
US$ 21.52
